Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q2 2026 Earnings Presentation
13 slides from Autolus Therapeutics's earnings presentation, Aug 11, 2026
Slide 1: Q2 2026 Financial Results and Business Updates
Q2 2026 Financial Results and Business Updates August 11, 2026 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Agenda
Developing and Delivering a New Generation of T Cell Therapies Agenda • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian I
Slide 4: Strong AUCATZYL sales growth in Q2 2026
Developing and Delivering a New Generation of T Cell Therapies Strong AUCATZYL® sales growth in Q2 2026 AUCATZYL Global Net Product Revenue Q2 2026 1H 2026 $45.7 million $71.9 million +119% year-over-year +140% year-over-year Penetration into US market deepening with 82 U.S. Authorized Treatment Cen
Slide 5: Executing to plan with momentum in 2026
Developing and Delivering a New Generation of T Cell Therapies Executing to plan with momentum in 2026 2026 Expectations & Financial Guidance Commercial Expansion Achieved: Increase commercial Gross Margin footprint in the US to more FY 2026 Net than 80 treatment centers Product Revenue Achieved: Sh
Slide 6: Path to profitability in the r/r B-ALL business
Developing and Delivering a New Generation of T Cell Therapies Path to profitability in the r/r B-ALL business Optimizing the operating model and driving cost efficiency Increasing volumes and operational efficiency initiatives producing gross margin improvements We are here Launch: Establish consis
Slide 7: Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL Anticipated news flow and data catalysts for ongoing pipeline programs Timing Program Update Indication Trial CARLYSLE End of 2026 Obe-cel Longer-term follow up data
Slide 8: Upcoming data update: BOBCAT Trial in Progressive MS
Developing and Delivering a New Generation of T Cell Therapies Upcoming data update: BOBCAT Trial in Progressive MS Patient and physician interest is high; trial enrollment continues on track Q1 2027 2H 2027 Preliminary Phase 1 Data: Targeting ACTRIMS Full Phase 1 Data • Total 12 patients • Total 18
Slide 9: Financial Results
Financial Results
Slide 10: Financial summary – key metrics
Developing and Delivering a New Generation of T Cell Therapies Financial summary – key metrics* USD ($’ 000) Q2 2026 Q2 2025 Variance Product revenue, net 45,672 20,923 24,749 Cost and operating expenses: Cost of sales (20,468) (24,445) 3,977 Research and development expenses, net (27,898) (27,430)
Slide 11: Conclusion
Conclusion
Slide 12: Autolus is positioned for value creation
Developing and Delivering a New Generation of T Cell Therapies Autolus is positioned for value creation Obe-cel product franchise supports multiple growth opportunities Initial Indication: Adult r/r B-ALL Pipeline expansion opportunities Strong execution and market expansion grow future commercial p
Slide 13: Thank you
Thank you Autolus.com